Clorox's $2.25bn Acquisition of GOJO Industries
- 3 days ago
- 6 min read
By Ifeakachuku Ifeneziuche, Vikram Kumar, Benjamin Carr and Nikhil Dewan, Palamdeep Virk (University of Warwick); Amin Ouamar, Gilles Michaud and Marc Bellon (HEC Paris)
Photo: Clay Banks (Unsplash)
Overview of the deal
Acquirer:Â The Clorox Company (NYSE: CLX)
Target:Â GOJO Industries
Implied Equity Value: US$2.25 billion
Total Transaction Size: US$2.25 billion, all-cash, including approximately US$330 million of anticipated tax benefits, resulting in a net purchase price of ~US$1.92 billion
Announced Date: 22 January 2026
Expected Close Date: Before the end of Clorox's fiscal year 2026, subject to regulatory approvals and customary closing conditions
Target Advisor:Â Â Harris Williams (financial); Jones Day (legal)
Acquirer Advisor:Â Centerview Partners (financial); Cooley LLP (legal)
On 22 January 2026, The Clorox Company announced a definitive agreement to acquire GOJO Industries, the manufacturer of the PURELL hand-sanitiser brand, in an all-cash transaction valued at US$2.25 billion. The headline valuation includes anticipated tax benefits of approximately US$330 million, implying a net purchase price of roughly US$1.92 billion. Clorox expects the transaction to close before the end of its fiscal year 2026, subject to regulatory approval and customary closing conditions, and intends to finance the acquisition primarily through debt.
This deal represents a strategic expansion of Clorox's Health and Wellness segment, moving beyond surface disinfection into skin health and hand hygiene through the addition of PURELL, the market-leading hand hygiene brand. GOJO generates approximately US$800 million in annual revenue, with more than 80% derived from B2B and institutional channels, supported by an installed base of roughly 20 million dispensers globally. This profile increases Clorox's exposure to more stable, recurring demand, while strengthening its presence across healthcare, education, workplace, and public facilities. Clorox expects the transaction to deliver at least US$50 million of run-rate cost synergies, primarily from procurement, supply chain, and overhead efficiencies.
Strategically, the acquisition strengthens Clorox's position in the health and wellness segment by adding a category-leading brand in hand hygiene with strong penetration in healthcare and institutional channels. The deal enables Clorox to diversify its revenue base, deepen its exposure to higher-margin professional markets, and leverage its scale in distribution, procurement, and marketing to accelerate PURELL's retail and international growth. Management has highlighted expected cost synergies from supply chain integration and overhead efficiencies, as well as potential revenue synergies through cross-selling and expanded global reach. The transaction also pre-empts competitive pressures in the infection-prevention space, where large consumer health and cleaning product companies continue to consolidate to gain scale and resilience. Overall, the acquisition reflects Clorox's strategy to pursue disciplined, bolt-on growth opportunities that enhance long-term earnings and shareholder value.
Company Details (Acquirer - The Clorox Company)
The Clorox Company is a multinational manufacturer and marketer of consumer and professional cleaning, hygiene, and lifestyle products. The company operates across approximately 25 countries and sells into around 100 markets worldwide. Its portfolio is organised into four operating segments: Health and Wellness, Household, Lifestyle, and International. In addition to its core consumer brands -- including Clorox bleach, Pine-Sol, Brita, Burt's Bees and Hidden Valley -- Clorox provides professional disinfection and hygiene solutions through its CloroxPro and Clorox Healthcare businesses. The company serves both retail consumers and institutional clients, with a strong presence in North America.
Founded: 1913
Headquartered: Oakland, California, USA
CEO: Linda Rendle (Chair and CEO)
Number of employees: ~7,600 (as of 30 June 2025)
Primary Listing: NYSE (CLX)
Market Cap*: USD $14.46bn (as of 09 February 2026)
EV: USD $17.03bn
LTM Revenue:Â USD $6.76bn (TTM ended 31 December 2025)
LTM EBITDA:Â USD $1.30bn (TTM ended 31 December 2025)
LTM EV/Revenue:Â 2.52x
LTM EV/EBITDA:Â 13.15x
Recent Transactions: Divestiture of Better Health VMS business (completed September 2024); divestiture of Argentina business (completed March 2024); contractual obligation to acquire P&G's 20% interest in the Glad joint venture upon termination
Company Details (Target - GOJO Industries)
GOJO Industries is a privately held American manufacturer operating in the skin health, hygiene, and infection-prevention industry. Founded in 1946 and headquartered in Akron, Ohio, the company is best known as the creator of the Purell brand, a global leader in hand sanitizers. GOJO develops and manufactures hand hygiene products, soaps, sanitizers, surface disinfectants, and dispensing systems serving healthcare facilities, schools, foodservice operators, and commercial institutions worldwide. The company operates primarily in business-to-business (B2B) channels, with additional retail distribution, focusing on products designed to reduce the spread of illness and improve public health outcomes. GOJO's competitive advantages include strong brand equity in Purell, deep relationships in healthcare and institutional channels, vertically integrated manufacturing capabilities, and a reputation for product efficacy and regulatory compliance in infection prevention.
Founded: 1946
Headquartered: Akron, Ohio, USA
CEO: Carey Jaros
Number of employees: 2500
Market Cap:Â N/A (privately held)
Enterprise Value: N/A
LTM Revenue:Â USD $800m
LTM EBITDA:Â N/A
Projections and Assumptions
Short-Term Consequences
Clorox plans to achieve at least US$50 million in annual cost synergies through operational efficiencies, procurement scale, distribution integration, and streamlined administrative structures. However, the initial year is expected to see a temporary increase in leverage, with debt financing underpinning most of the purchase price.
In terms of product offering, adding the Purell brand and GOJO's hygiene portfolio expands Clorox's presence in health and wellness -- a category with favorable macro tailwinds and stable demand, especially in institutional B2B channels.
Market reaction following the acquisition announcement has been mixed, with some sources showing short-term share price volatility reflecting skepticism about integration execution and long-term debt impact.
Long-Term Upsides
The acquisition would strengthen Clorox's exposure to structurally growing hygiene categories, which benefit from sustained post-pandemic demand and increasing institutional hygiene standards. GOJO's PURELL brand is deeply embedded across healthcare, food service, and commercial environments, this would improve Clorox's position in essential hygiene products with consistent, recurring demand and predictable long-term revenue.
The transaction would significantly expand Clorox's presence in the professional and institutional segment, which offers more predictable and contract-based revenue streams compared to retail markets. GOJO's established relationships with hospitals, schools and commercial facilities, improving revenue visibility and reducing exposure to fluctuations in consumer spending.
The addition of GOJO's premium-positioned products would enhance Clorox's overall margin profile through favourable pricing power and brand strength. PURELL captures premium pricing due to its strong brand equity and trusted medical-grade perception, which in turn supports higher gross margins and contributes to long-term operating margin expansion across combined entities.
Operational efficiencies and procurement scale would create long-term cost synergies, improving profitability and cash flow generation. The combined entity would benefit from economies of scale in manufacturing, sourcing, logistics and administrative functions, reducing per-unit costs and increasing operating efficiency over time.
The acquisition would enhance Clorox's innovation capabilities by integrating GOJO's specialised expertise in healthcare-grade sanitisation and dispensing systems. This would support the development of new hygiene solutions and adjacent products, enabling long-term growth through product innovation and category expansion.
The structure of the transaction also provides long-term benefits for shareholders of Clorox. Although the headline acquisition price is $2.25 billion, the $300 million in tax benefits reduce the effective purchase price to roughly $1.9 billion. Thereby lowering the overpaying risk associated with the premium paid, if synergies are not realised. In addition, the all-cash nature of the deal ensures that ownership is non-dilutive to existing Clorox shareholders. As a result, any future value created through synergy realisation (such as management's guidance of at least $50 million in run-rate cost synergies) will accrue entirely to the existing shareholder base rather than being spread thinly across a larger base of shareholders. This supports future per-share earnings growth, as the acquisition is expected to be neutral to Clorox's adjusted EPS in the first year and accretive to adjusted EPS in the years after.
Risks and Uncertainties
Clorox's acquisition of GOJO Industries at the price of $2.25 billion is very expensive, especially as the deal is fully financed using debt. After the announcement of the deal, S&P Global Ratings did put Clorox on CreditWatch Negative due to the concern that the increased leverage ratio could impact financial flexibility. The management does believe that EPS will be positive in the second year, but that depends on if the synergies projected by the management team do occur.
There is also the risk that the transaction could get reviewed by the FTC as the combination could lead to anti-competitive effects, even though they seem to operate in different markets, institutional surface disinfectants and skin care products.
Also, Clorox had recently announced that they had completed the 5-year SAP Enterprise Resource Planning upgrade, which means many of the GOJO system would need to be migrated to this platform, leading to extra costs. GOJO will also have to adapt from being a family owned B2B sales specialist to Clorox's B2C retail model, which could put pressure on the management team. The expansion of Purell, would lead to high marketing costs and negotiations with retailers for shelf space, and slow adoption, all of which could create unforeseen costs.
Overall, while the long term strategic outlook is strong, the success will depend on Clorox's ability to complete this complicated integration while dealing with the operational challenges and the debt burden.
"This is a compelling acquisition that evolves our portfolio and scales our fastest-growing, most profitable operating segment, Health and Wellness." - Linda Rendle, Chair and CEO, The Clorox Company